Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Ruling Bloc’s Draft Budget Policy Says Off-Year Revisions Could Alter, but DPP Calls for Explicit Mention of Repeal
The opposition Democratic Party for the People (DPP) reiterated the need to abolish the “off-year” drug price revisions and demanded that the ruling coalition partners spell this out in the FY2025 budget guidelines during three-party talks held on December 16.…
To read the full story
REGULATORY
- Provider-Payer Tug-of-War Takes Shape over FY2027 Drug Price Revision
October 8, 2026
- SCARDA, Thai Vaccine Institute Link Up on KM Biologics’ Dengue Shot
October 7, 2026
- MHLW Opens Applications for Innovation Fund’s Ecosystem Program
October 7, 2026
- Takaichi Puts Health Security on Crisis Management Investment Agenda
October 6, 2026
- Japan Has Limited Drug Pricing Cards to Play on MFN, Should Expand CEA: MOF Official
October 5, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…